

METHOCARBAMOL- methocarbamol tablet
Aphena Pharma Solutions - Tennessee, LLC


Methocarbamol Tablets, USP

R x only
Solco Healthcare U.S., LLC

DESCRIPTION

Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, are a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

The chemical name of methocarbamol is 3-(2-methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula $C_{11}H_{15}NO_5$. Its molecular weight is 241.24. The structural formula is shown below.



Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and *n*-hexane.

Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration. Methocarbamol tablets, USP 500 mg and 750 mg contain the following inactive ingredients: povidone, sodium starch glycolate and magnesium stearate.

CLINICAL PHARMACOLOGY

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

Pharmacokinetics

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

Special populations

Elderly

The mean (\pm SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean (\pm SD) age, 69 (\pm 4) years) was slightly prolonged compared to a younger (mean (\pm SD) age, 53.3 (\pm 8.8) years), healthy population (1.5 (\pm 0.4) hours versus 1.1 (\pm 0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

Renally impaired

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (\pm SD) elimination half-life in these two groups was similar: 1.2 (\pm 0.6) versus 1.1 (\pm 0.3) hours, respectively.

Hepatically impaired

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (\pm SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (\pm 1.62) hours and 1.11 (\pm 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

INDICATIONS AND USAGE

Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

CONTRAINDICATIONS

Methocarbamol tablets, USP are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

WARNINGS

Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and

congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see **Precautions, Pregnancy**).

Use In Activities Requiring Mental Alertness

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

PRECAUTIONS

Information for patients

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

Drug interactions

See **Warnings** and **Precautions** for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Drug/laboratory test interactions

Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, mutagenesis, impairment of fertility

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

Pregnancy

Teratogenic effects - Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets, USP should be given to a pregnant woman only if clearly needed.

Safe use of Methocarbamol tablets, USP has not been established with regard to

possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see **Warnings**).

Nursing mothers

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets, USP are administered to a nursing woman.

Pediatric use

Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

ADVERSE REACTIONS

Adverse reactions reported coincident with the administration of methocarbamol include:

Body as a whole:

Anaphylactic reaction, angioneurotic edema, fever, headache

Cardiovascular system:

Bradycardia, flushing, hypotension, syncope, thrombophlebitis

Digestive system:

Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting

Hemic and lymphatic system:

Leukopenia

Immune system:

Hypersensitivity reactions

Nervous system:

Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

Skin and special senses:

Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

DOSAGE AND ADMINISTRATION

Methocarbamol tablets, USP, 500 mg – Adults:

Initial dosage: 3 tablets q.i.d.

Maintenance dosage: 2 tablets q.i.d.

Methocarbamol tablets, USP: 750 mg – Adults:

Initial dosage: 2 tablets q.i.d.

Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

HOW SUPPLIED

Methocarbamol tablets, USP

500 mg tablets are round standard convex, scored, white to off-white tablet, debossed S 225 on one side and plain on the reverse side.

They are supplied as follows:

Bottles of 100 NDC 51407-467-01

Bottles of 500 NDC 51407-467-05

Methocarbamol tablets, USP

750 mg tablets are modified capsule shape, white to off-white tablet, debossed S 226 on one side and plain on the reverse side.

They are supplied as follows:

Bottles of 100 NDC 51407-468-01

Bottles of 500 NDC 51407-468-05

Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F).

[see USP Controlled Room Temperature].

Dispense in tight container.

Distributed by:

Solco Healthcare U.S., LLC

Somerset, NJ 08873, USA

Manufactured by:

Princeton Laboratories

3241 Woodpark Blvd, Charlotte, NC 28206

Revised: 01/2021

R x only

Marketed/Packaged by:

GSMS, Inc.

Camarillo, CA USA 93012

Repackaging Information

Please reference the ***How Supplied*** section listed above for a description of individual tablets. This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations. The package configurations available from Aphena are listed below:

| Count 750 mg 500 mg | | |
|----------------------------|--------|--------|
| | | 71610- |
| 30 | - | 599-30 |
| | 71610- | 71610- |
| 60 | 598-53 | 599-53 |
| | 71610- | 71610- |
| 90 | 598-60 | 599-60 |
| | 71610- | 71610- |
| 120 | 598-70 | 599-70 |
| | 71610- | 71610- |

| | | |
|-----|--------|--------|
| 180 | 598-80 | 599-80 |
| | | 71610- |
| 240 | - | 599-90 |
| | | 71610- |
| 270 | - | 599-92 |

Store between 20°-25°C (68°-77°F). See USP Controlled Room Temperature. Dispense in a tight light-resistant container as defined by USP. Keep this and all drugs out of the reach of children.

Repackaged by:




Cookeville, TN 38506

20210930JH

PRINCIPAL DISPLAY PANEL - 750 mg

NDC 71610-598 - Methocarbamol, USP 750 mg Tablets - Rx Only



PRINCIPAL DISPLAY PANEL - 500 mg

NDC 71610-599 - Methocarbamol, USP 500 mg Tablets - Rx Only

Methocarbamol, USP

500mg 30 Tablets

NDC# 71610-0599-30

Store between 20-25 degrees C(68-77 degrees F).
See USP Controlled Room Temperature.
Dispense in a tight light-resistant container
as defined by USP.
Keep this and all drugs out of the reach of children

MFG BY: Princeton Laboratories
Charlotte, NC
RPKG BY: Aphena Pharma, Cookeville, TN 38506

RX Only

Methocarbamol, USP

500mg 30 Tablets

71610-0599-30

12345

10371610599305

S/N P704463

BATCH SWJ7289

EXP 12/2024

METHOCARBAMOL

methocarbamol tablet

| Product Information | | | | |
|--|----------------------------|---|----------------------|------------------------------|
| Product Type | | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:71610-598(NDC:51407-468) |
| Route of Administration | | ORAL | | |
| | | | | |
| Active Ingredient/Active Moiety | | | | |
| Ingredient Name | | | Basis of Strength | Strength |
| METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X) | | | METHOCARBAMOL | 750 mg |
| | | | | |
| Inactive Ingredients | | | | |
| Ingredient Name | | | | Strength |
| POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) | | | | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) | | | | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | | | | |
| | | | | |
| Product Characteristics | | | | |
| Color | white (white to off-white) | | Score | no score |
| Shape | CAPSULE (capsule-shaped) | | Size | 18mm |
| Flavor | | | Imprint Code | S226 |
| Contains | | | | |
| | | | | |
| Packaging | | | | |
| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
| 1 | NDC:71610-598- | 60 in 1 BOTTLE; Type 0: Not a Combination | 09/09/2021 | |

| | | | | |
|---|------------------|--|------------|--|
| 1 | 53 | Product | 09/09/2021 | |
| 2 | NDC:71610-598-60 | 90 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |
| 3 | NDC:71610-598-70 | 120 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |
| 4 | NDC:71610-598-80 | 180 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| ANDA | ANDA086988 | 01/01/1982 | |

METHOCARBAMOL

methocarbamol tablet

Product Information

| | | | |
|-------------------------|-------------------------|--------------------|------------------------------|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:71610-599(NDC:51407-467) |
| Route of Administration | ORAL | | |

Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength |
|---|-------------------|----------|
| METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X) | METHOCARBAMOL | 500 mg |

Inactive Ingredients

| Ingredient Name | Strength |
|---|----------|
| POVIDONE, UNSPECIFIED (UNII: FZ989GH94E) | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | |

Product Characteristics

| | | | |
|----------|----------------------------|--------------|----------|
| Color | white (white to off-white) | Score | 2 pieces |
| Shape | ROUND | Size | 15mm |
| Flavor | | Imprint Code | S;225 |
| Contains | | | |

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---|----------------------|--------------------|
| 1 | NDC:71610-599-30 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |

| | | | | |
|----------|------------------|--|------------|--|
| 2 | NDC:71610-599-53 | 60 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |
| 3 | NDC:71610-599-60 | 90 in 1 BOTTLE; Type 0: Not a Combination Product | 09/09/2021 | |
| 4 | NDC:71610-599-70 | 120 in 1 BOTTLE; Type 0: Not a Combination Product | 10/19/2021 | |
| 5 | NDC:71610-599-80 | 180 in 1 BOTTLE; Type 0: Not a Combination Product | 09/21/2021 | |
| 6 | NDC:71610-599-90 | 240 in 1 BOTTLE; Type 0: Not a Combination Product | 09/21/2021 | |
| 7 | NDC:71610-599-92 | 270 in 1 BOTTLE; Type 0: Not a Combination Product | 09/21/2021 | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| ANDA | ANDA086989 | 01/01/1982 | |

Labeler - Aphena Pharma Solutions - Tennessee, LLC (128385585)

Establishment

| Name | Address | ID/FEI | Business Operations |
|--|---------|-----------|------------------------------|
| Aphena Pharma Solutions - Tennessee, LLC | | 128385585 | REPACK(71610-598, 71610-599) |

Revised: 11/2021

Aphena Pharma Solutions - Tennessee, LLC